Literature DB >> 18559559

Long-term stability of human aflatoxin B1 albumin adducts assessed by isotope dilution mass spectrometry and high-performance liquid chromatography-fluorescence.

Peter F Scholl1, John D Groopman.   

Abstract

The measurement of the aflatoxin B(1)-lysine serum albumin adduct in human blood samples is the most facile biomarker for the assessment of chronic exposure to aflatoxin B(1). Many technologies have been developed for the measurement of this protein adduct including immunoassays, high-performance liquid chromatography (HPLC) with fluorescence detection, and a newly developed isotope-dilution mass spectrometry method. Irrespective of the technology used to determine this adduct level, an important question remains about the long-term stability of this damage product in stored samples. To address this issue, 19 human serum samples that had been previously analyzed for the aflatoxin B(1)-lysine adduct by high-performance liquid chromatography-fluorescence in 1989 were re-analyzed by isotope dilution mass spectrometry after storage at -80 degrees C. The adduct concentrations measured by these two techniques were identical within 4% over the range 5 to 100 pg of aflatoxin B(1)-lysine/mg albumin. In addition, the specific chemical structure of the aflatoxin B(1)-lysine adduct in human samples was confirmed for the first time by collision-induced dissociation full scan mass spectrometry analysis of the protonated adduct molecular ion. These results illustrate that the aflatoxin B(1)-lysine serum albumin adduct can be stable in human serum stored at -80 degrees C since 1989, and this provides confidence for the measurement of this biomarker in repository samples from epidemiologic investigations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18559559      PMCID: PMC2586885          DOI: 10.1158/1055-9965.EPI-07-2926

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  18 in total

1.  Quantitative analysis and chronic dosimetry of the aflatoxin B1 plasma albumin adduct Lys-AFB1 in rats by isotope dilution mass spectrometry.

Authors:  Peter F Scholl; Les McCoy; Thomas W Kensler; John D Groopman
Journal:  Chem Res Toxicol       Date:  2006-01       Impact factor: 3.739

2.  Analysis of aflatoxin B1-lysine adduct in serum using isotope-dilution liquid chromatography/tandem mass spectrometry.

Authors:  Leslie F McCoy; Peter F Scholl; Rosemary L Schleicher; John D Groopman; Carissa D Powers; Christine M Pfeiffer
Journal:  Rapid Commun Mass Spectrom       Date:  2005       Impact factor: 2.419

3.  Chemical and physical properties of the major serum albumin adduct of aflatoxin B1 and their implications for the quantification in biological samples.

Authors:  G Sabbioni
Journal:  Chem Biol Interact       Date:  1990       Impact factor: 5.192

4.  Isolation and characterization of the major serum albumin adduct formed by aflatoxin B1 in vivo in rats.

Authors:  G Sabbioni; P L Skipper; G Büchi; S R Tannenbaum
Journal:  Carcinogenesis       Date:  1987-06       Impact factor: 4.944

5.  The aflatoxin-lysine adduct quantified by high-performance liquid chromatography from human serum albumin samples.

Authors:  G Sabbioni; S Ambs; G N Wogan; J D Groopman
Journal:  Carcinogenesis       Date:  1990-11       Impact factor: 4.944

6.  Quantitative comparison of aflatoxin B1 serum albumin adducts in humans by isotope dilution mass spectrometry and ELISA.

Authors:  Peter F Scholl; Paul C Turner; Anne E Sutcliffe; Abdoulaye Sylla; Momadou S Diallo; Marlin D Friesen; John D Groopman; Christopher P Wild
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-04       Impact factor: 4.254

7.  Dietary intake of aflatoxins and the level of albumin-bound aflatoxin in peripheral blood in The Gambia, West Africa.

Authors:  C P Wild; G J Hudson; G Sabbioni; B Chapot; A J Hall; G N Wogan; H Whittle; R Montesano; J D Groopman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1992 Mar-Apr       Impact factor: 4.254

8.  Aflatoxin-albumin adducts: a basis for comparative carcinogenesis between animals and humans.

Authors:  C P Wild; R Hasegawa; L Barraud; S Chutimataewin; B Chapot; N Ito; R Montesano
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1996-03       Impact factor: 4.254

9.  Serum albumin adducts in the molecular epidemiology of aflatoxin carcinogenesis: correlation with aflatoxin B1 intake and urinary excretion of aflatoxin M1.

Authors:  L S Gan; P L Skipper; X C Peng; J D Groopman; J S Chen; G N Wogan; S R Tannenbaum
Journal:  Carcinogenesis       Date:  1988-07       Impact factor: 4.944

10.  DNA conformation mediates aflatoxin B1-DNA binding and the formation of guanine N7 adducts by aflatoxin B1 8,9-exo-epoxide.

Authors:  V M Raney; T M Harris; M P Stone
Journal:  Chem Res Toxicol       Date:  1993 Jan-Feb       Impact factor: 3.739

View more
  19 in total

1.  Association of Aflatoxin and Gallbladder Cancer.

Authors:  Jill Koshiol; Yu-Tang Gao; Michael Dean; Patricia Egner; Chirag Nepal; Kristine Jones; Bingsheng Wang; Asif Rashid; Wen Luo; Alison L Van Dyke; Catterina Ferreccio; Michael Malasky; Ming-Chang Shen; Bin Zhu; Jesper B Andersen; Allan Hildesheim; Ann W Hsing; John Groopman
Journal:  Gastroenterology       Date:  2017-04-17       Impact factor: 22.682

2.  Aflatoxin B1 exposure increases the risk of cirrhosis and hepatocellular carcinoma in chronic hepatitis B virus carriers.

Authors:  Yu-Ju Chu; Hwai-I Yang; Hui-Chen Wu; Jessica Liu; Li-Yu Wang; Sheng-Nan Lu; Mei-Hsuan Lee; Chin-Lan Jen; San-Lin You; Regina M Santella; Chien-Jen Chen
Journal:  Int J Cancer       Date:  2017-05-26       Impact factor: 7.396

3.  Aflatoxin B1 exposure increases the risk of hepatocellular carcinoma associated with hepatitis C virus infection or alcohol consumption.

Authors:  Yu-Ju Chu; Hwai-I Yang; Hui-Chen Wu; Mei-Hsuan Lee; Jessica Liu; Li-Yu Wang; Sheng-Nan Lu; Chin-Lan Jen; San-Lin You; Regina M Santella; Chien-Jen Chen
Journal:  Eur J Cancer       Date:  2018-03-20       Impact factor: 9.162

Review 4.  Present and future directions of translational research on aflatoxin and hepatocellular carcinoma. A review.

Authors:  Gerald N Wogan; Thomas W Kensler; John D Groopman
Journal:  Food Addit Contam Part A Chem Anal Control Expo Risk Assess       Date:  2011-06-01

Review 5.  Aflatoxin: a 50-year odyssey of mechanistic and translational toxicology.

Authors:  Thomas W Kensler; Bill D Roebuck; Gerald N Wogan; John D Groopman
Journal:  Toxicol Sci       Date:  2010-09-29       Impact factor: 4.849

6.  Aflatoxin B1 exposure, hepatitis B virus infection, and hepatocellular carcinoma in Taiwan.

Authors:  Hui-Chen Wu; Qiao Wang; Hwai-I Yang; Habibul Ahsan; Wei-Yann Tsai; Li-Yu Wang; Shu-Yuan Chen; Chien-Jen Chen; Regina M Santella
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-03       Impact factor: 4.254

7.  Global DNA methylation in a population with aflatoxin B1 exposure.

Authors:  Hui-Chen Wu; Qiao Wang; Hwai-I Yang; Wei-Yann Tsai; Chien-Jen Chen; Regina M Santella
Journal:  Epigenetics       Date:  2013-07-18       Impact factor: 4.528

8.  Reduced aflatoxin exposure presages decline in liver cancer mortality in an endemic region of China.

Authors:  Jian-Guo Chen; Patricia A Egner; Derek Ng; Lisa P Jacobson; Alvaro Muñoz; Yuan-Rong Zhu; Geng-Sun Qian; Felicia Wu; Jian-Min Yuan; John D Groopman; Thomas W Kensler
Journal:  Cancer Prev Res (Phila)       Date:  2013-08-20

9.  Carcinogenic effects of aflatoxin B1 among wheat handlers.

Authors:  Amal Saad-Hussein; Mona M Taha; Safia Beshir; Eman M Shahy; Weam Shaheen; Mohamed Elhamshary
Journal:  Int J Occup Environ Health       Date:  2014 Jul-Sep

10.  Aflatoxin exposure during the first 1000 days of life in rural South Asia assessed by aflatoxin B₁-lysine albumin biomarkers.

Authors:  John D Groopman; Patricia A Egner; Kerry J Schulze; Lee S-F Wu; Rebecca Merrill; Sucheta Mehra; Abu A Shamim; Hasmot Ali; Saijuddin Shaikh; Alison Gernand; Subarna K Khatry; Steven C LeClerq; Keith P West; Parul Christian
Journal:  Food Chem Toxicol       Date:  2014-10-13       Impact factor: 6.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.